En undersøgelse af effektivitet og sikkerhed af ALZ-801 i APOE4/4 tidlige AD-emner (APOLLOE4)
En fase 3, multicenter, randomiseret, dobbeltblind, placebokontrolleret undersøgelse af effektivitet, sikkerhed og biomarkøreffekter af ALZ-801 hos forsøgspersoner med tidlig Alzheimers sygdom og APOE4/4-genotype
This study is being conducted to evaluate the safety and efficacy of ALZ-801 in Early Alzheimer's disease (AD) subjects with the APOE4/4 genotype. This is a double-blind, randomized trial with one dose of ALZ-801 compared to placebo.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
This is a multi-center, double-blind study that will evaluate 265 mg twice daily (BID) of ALZ-801, an oral tablet, over 78 weeks as a treatment for subjects (50-80 years old) with Early AD who are homozygous for the ε4 allele of the apolipoprotein gene (APOE4 homozygous or APOE4/4). The primary efficacy outcome assessment is a measure of cognition (ADAS-cog 13). Additional measures of global and functional impairments will also be assessed. Imaging and soluble biomarkers of AD and neurodegeneration will be measured and a sub-study to evaluate cerebrospinal fluid (CSF) biomarkers is also included.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Fase 3
Kontakter og lokationer
Studiesteder
-
-
British Columbia
-
Kelowna, British Columbia, Canada, V1Y 1Z9
- OCT Research ULC (dba Okanagan Clinical Trials)
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3S 1N2
- Centricity Research
-
New Minas, Nova Scotia, Canada, B4N 3R7
- Centricity Research
-
-
Ontario
-
Ottawa, Ontario, Canada, K1Z 1G3
- Recherches Neuro-Hippocampe Inc., d/b/a Ottawa Memory Clinic
-
Peterborough, Ontario, Canada, K9H 2P4
- Kawartha Centre - Redefining Healthy Aging
-
Toronto, Ontario, Canada, M3B 2S7
- Toronto Memory Program
-
-
Quebec
-
Gatineau, Quebec, Canada, J8T 8J1
- Recherches Neuro-Hippocampe Inc. d/b/a Clinique de la Mémoire de l'Outaouais
-
-
-
-
-
Bristol, Det Forenede Kongerige, BS32 4SY
- Re:Cognition Health Ltd Bristol
-
London, Det Forenede Kongerige, EC2Y 8EA
- St. Pancras Clinical Research
-
Winchester, Det Forenede Kongerige, SO21 1HU
- Re-Cognition Health Ltd Winchester
-
-
Devon
-
Plymouth, Devon, Det Forenede Kongerige, PL6 8BT
- Re-Cognition Health Ltd Plymouth
-
-
Greater London
-
London, Greater London, Det Forenede Kongerige, W1G 9JF
- Re-Cognition Health Ltd London
-
-
North Lanarkshire
-
Motherwell, North Lanarkshire, Det Forenede Kongerige, ML1 4UF
- NeuroClin Glasgow Ltd
-
-
Surrey
-
Guildford, Surrey, Det Forenede Kongerige, GU2 7YD
- Re-Cognition Health Ltd Guildford
-
-
West Midlands
-
Birmingham, West Midlands, Det Forenede Kongerige, B16 8LT
- Re-Cognition Health Ltd Birmingham
-
-
-
-
Arizona
-
Phoenix, Arizona, Forenede Stater, 85004
- Xenoscience
-
Scottsdale, Arizona, Forenede Stater, 85297
- CCT Research
-
Sun City, Arizona, Forenede Stater, 85351
- Banner Sun Health Research Institute
-
-
California
-
Costa Mesa, California, Forenede Stater, 92626
- ATP Clinical Research
-
Irvine, California, Forenede Stater, 92780
- Tilda Research
-
La Jolla, California, Forenede Stater, 92037
- UCSD Shiley-Marcos Alzheimer's Disease Research Center
-
Lomita, California, Forenede Stater, 90717
- Torrance Clinical Research Institute
-
Long Beach, California, Forenede Stater, 90806
- Collaborative NeuroScience Network LLC
-
Palo Alto, California, Forenede Stater, 94304
- Stanford University
-
Pasadena, California, Forenede Stater, 91105
- SC3 Research Group
-
Sacramento, California, Forenede Stater, 95816
- Sutter Health
-
-
Florida
-
Atlantis, Florida, Forenede Stater, 33462
- JEM Research Institute, Headlands Site
-
Bradenton, Florida, Forenede Stater, 34205
- Bradenton Research Center
-
Hialeah, Florida, Forenede Stater, 33016
- Galiz Research
-
Jupiter, Florida, Forenede Stater, 33458
- Alphab Global Research
-
Lady Lake, Florida, Forenede Stater, 32159
- Charter Research
-
Maitland, Florida, Forenede Stater, 32751
- K2 Medical Research, LLC
-
Miami, Florida, Forenede Stater, 33137
- Miami Jewish Health
-
Miami, Florida, Forenede Stater, 33144
- Y & L Advance Health Care, Inc /DBA Elite Clinical Research
-
Miami Beach, Florida, Forenede Stater, 33140
- Mount Sinai Medical Center
-
Naples, Florida, Forenede Stater, 34105
- Aqualane Clinical Research
-
Orlando, Florida, Forenede Stater, 32819
- Headlands Research Orlando
-
Orlando, Florida, Forenede Stater, 32803
- Charter Research
-
Palm Beach Gardens, Florida, Forenede Stater, 33410
- Advanced Research Consultants
-
Pompano Beach, Florida, Forenede Stater, 33064
- Quantum CNS Clinical Research
-
Port Orange, Florida, Forenede Stater, 32127
- Progressive Medical Research
-
Stuart, Florida, Forenede Stater, 34997
- ALZ Research and Treatment Center (A.R.T.C.)
-
Wellington, Florida, Forenede Stater, 33414
- ALZ Research and Treatment Center (A.R.T.C.)
-
West Palm Beach, Florida, Forenede Stater, 33407
- Premiere Research Institute
-
-
Georgia
-
Columbus, Georgia, Forenede Stater, 31909
- Columbus Memory Center
-
Decatur, Georgia, Forenede Stater, 30030
- Sandhill Research, LLC
-
-
Indiana
-
Fort Wayne, Indiana, Forenede Stater, 46804
- Fort Wayne Neurological Center
-
-
Louisiana
-
Shreveport, Louisiana, Forenede Stater, 71103
- Louisiana State University Health Sciences Center (LSUHSC)
-
-
Massachusetts
-
Plymouth, Massachusetts, Forenede Stater, 02360
- Headlands Research Eastern MA
-
-
Nevada
-
Las Vegas, Nevada, Forenede Stater, 89106
- WR-CRCN
-
-
New Jersey
-
Toms River, New Jersey, Forenede Stater, 08755
- Advanced Memory Research Center
-
-
New York
-
Albany, New York, Forenede Stater, 12208
- Neurological Associates of Albany
-
New York, New York, Forenede Stater, 10016
- NYU Alzheimer's Disease Research Center
-
Orangeburg, New York, Forenede Stater, 10962
- Kline Institute for Psychiatric Research
-
Rochester, New York, Forenede Stater, 14620
- University of Rochester Medical Center
-
Staten Island, New York, Forenede Stater, 10312
- Richmond Behavioral Associates
-
-
North Carolina
-
Greensboro, North Carolina, Forenede Stater, 27410
- Triad Clinical Trials
-
Matthews, North Carolina, Forenede Stater, 28105
- AMC Research
-
-
Ohio
-
Canton, Ohio, Forenede Stater, 44718
- NeuroScience Research Center
-
Dayton, Ohio, Forenede Stater, 45459
- Neurology Diagnostics, Inc.
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Forenede Stater, 73106
- IPS Research
-
-
Oregon
-
Portland, Oregon, Forenede Stater, 97225
- Center for Cognitive Health
-
-
Pennsylvania
-
Abington, Pennsylvania, Forenede Stater, 19001
- Abington Neurological Associates
-
Allentown, Pennsylvania, Forenede Stater, 18104
- Lehigh Center for Clinical Research
-
-
Rhode Island
-
East Providence, Rhode Island, Forenede Stater, 02914
- Rhode Island Mood & Memory Research Institute
-
-
Tennessee
-
Nashville, Tennessee, Forenede Stater, 37212
- Vanderbilt Center for Cognitive Medicine
-
-
Texas
-
Houston, Texas, Forenede Stater, 77054
- UT Health Science Center at Houston
-
-
Virginia
-
Fairfax, Virginia, Forenede Stater, 22031
- Re:Cognition Health
-
-
Washington
-
Bellevue, Washington, Forenede Stater, 98007
- Northwest Clinical Research Center
-
-
Wisconsin
-
Milwaukee, Wisconsin, Forenede Stater, 53226
- Medical College of Wisconsin
-
-
-
-
-
Marseille, Frankrig, 13385
- Centre Hospitalier Universitaire de Marseille - Hôpital de la Timone
-
Montpellier, Frankrig, 43431
- Hopital Gui de Chauliac - CHRU de Montpellier
-
Paris, Frankrig, 75475
- Hopital Lariboisiere - Fernand-Widal - AP-HP
-
Rouen, Frankrig, 76031
- Centre Hospitalier Universitaire (CHU) Hopitaux de Rouen
-
Strasbourg, Frankrig, 67200
- Hopitaux Universitaires de Strasbourg Centre d'Investigation Clinique
-
Toulouse, Frankrig, 31059
- Centre de Recherche Clinique du Gerontopole - CHU Toulouse
-
Villeurbanne, Frankrig, 69100
- Centre de Recherche-Hopital Geriatrique de Charpennes
-
-
-
-
-
's-Hertogenbosch, Holland, 5223 LA
- Brain Research Center Den Bosch
-
Amsterdam, Holland, 1081 GN
- Brain Research Center Amsterdam
-
Zwolle, Holland, 8025 AZ
- Brain Research Center Zwolle
-
-
-
-
-
Reykjavik, Island, 101
- Memory Clinic, Landspitali University Hospital
-
-
-
-
-
Barcelona, Spanien, 08028
- Fundacia ACE - Institut Catala de Neurociencies Aplicadas
-
Madrid, Spanien, 28040
- Hospital Clinico San Carlos
-
Madrid, Spanien, 28027
- Clinica Universidad de Navarra
-
Pamplona, Spanien, 31008
- Clinica Universidad de Navarra
-
Terrassa, Spanien, 08221
- Hospital Universitari MutuaTerrassa
-
Valencia, Spanien, 46017
- Centro Hospital Universitario Dr. Preset
-
-
-
-
-
Brno, Tjekkiet, 656 91
- Fakultní nemocnice u sv. Anny v Brně (St. Anne's University Hospital)
-
Brno, Tjekkiet, 602 00
- Medica 111, Spol. s r.o. - Neurologicka a Rehabilitacni Ambulance Brno, Centralni Pracoviste v Brne
-
Prague, Tjekkiet, 160 00
- Neuropsychiatrie s.r.o.
-
Rychnov nad Kněžnou, Tjekkiet, 51601
- Vestra Clinics - Dedicated Research Clinics
-
-
-
-
-
Aachen, Tyskland, 52074
- University Hospital RWTH Aachen Neurological Study Center
-
München, Tyskland, 80336
- Klinikum der Universitaet Muenchen Innenstadt
-
Tübingen, Tyskland, 72076
- Universitätsklinik fuer Psychiatrie und Psychotherapie
-
Westerstede, Tyskland, 26655
- Studienzentrum Nord-West
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Clinical diagnosis of MCI or Mild Dementia due to AD consistent with the National Institute on Aging-Alzheimer's Association (NIA-AA) Working Group Criteria.
- Homozygous for the ε4 allele of the apolipoprotein E gene (APOE4/4).
- MMSE score at Screening of 22 to 30 (inclusive).
- CDR - Global score of 0.5 or 1 and CDR Memory Box Score of ≥ 0.5.
- RBANS delayed memory index score ≤ 85.
- Evidence of progressive memory loss over the last 12 months per investigator assessment
Exclusion Criteria:
- Brain magnetic resonance imaging (MRI) indicative of significant abnormality per central reader, other than AD related atrophy. Computed tomography (CT) scan acceptable for subjects who cannot undergo MRI.
- Diagnosis of neurodegenerative disorder other than AD.
- Diagnosis of major depressive disorder (MDD) within one year prior to screening.
- Currently taking memantine or has taken memantine within 12 weeks prior to the Baseline Visit.
- History of suicidal behavior within one year prior to screening or has ongoing suicidal ideation.
- History of seizures, excluding febrile seizures of childhood or a single distant seizure (> 5 years).
- Medically confirmed history of recent cerebral infarct or transient ischemic attack within one year prior to screening.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: ALZ-801
ALZ-801 265 mg BID tablet orally. Subjects will receive placebo in the morning and one tablet of ALZ-801 265 mg tablet in the evening during the first two weeks of the study; thereafter, they will receive a 265 mg tablet twice daily (BID). |
ALZ-801 tablet 265 mg once daily in the evening for the first 2 weeks, then ALZ-801 tablet 265 mg BID
Andre navne:
Placebo tablet BID |
|
Placebo komparator: Placebo
Subjects in the placebo treatment arm will receive placebo tablets BID throughout the study |
Placebo tablet BID |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Primary Cognitive Efficacy Endpoint (ADAS-Cog13)
Tidsramme: Baseline to Week 78
|
Change from baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale 13 (ADAS-Cog13) scores. The ADAS-Cog13 is a rater administered instrument that was designed to assess the severity of the dysfunction in the cognitive and noncognitive behaviors characteristic of persons with AD. The cognitive subscale of the ADAS-Cog13 consists of 13 items assessing areas of cognitive function most typically impaired in AD: orientation, verbal memory, language, praxis, delayed free recall, digit cancellation. The ADAS-Cog13 scale ranges from 0 to 85. Higher scores indicate greater disease severity. |
Baseline to Week 78
|
|
Incidence, Nature, and Severity of Treatment Emergent Adverse Events (TEAE)
Tidsramme: Entire study: approximately 82 weeks. (first dose of study drug until end of Safety Follow-up Visit at 28 +/- 7 days after the last dose (ie, 78-week treatment period plus 4-weeks follow-up after last dose up to total of 82 weeks)
|
Safety and tolerability as measured by incidence, nature and severity of treatment emergent adverse events (TEAE), serious TEAEs, and TEAEs leading to withdrawal. |
Entire study: approximately 82 weeks. (first dose of study drug until end of Safety Follow-up Visit at 28 +/- 7 days after the last dose (ie, 78-week treatment period plus 4-weeks follow-up after last dose up to total of 82 weeks)
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Key Secondary Endpoint (A-IADL-W)
Tidsramme: Baseline to Week 78
|
Change from baseline in Amsterdam - Instrumental Activities of Daily Living scores calculated using the weighted average method (A-IADL-W score). The A-IADL Questionnaire is a 70-item informant-based computerized questionnaire aimed at detecting deficits in complex functions at the early stages of AD. Instrumental ADL can be described as the activities necessary to function independently in society. These activities include, but are not limited to, cooking, doing finances, and shopping. They are complex everyday tasks, determined by multiple cognitive processes and controlled processing. They can be distinguished from basic ADL, which include basic self-care skills. The A-IADL-W has a score range of 0-100 and is calculated as follows: (sum of all scores / number of questions scored) × 25. For A-IADL-W, higher scores indicates worse functioning or more impairment. |
Baseline to Week 78
|
|
Key Secondary Endpoint (CDR-SB)
Tidsramme: Baseline to Week 78
|
Change from baseline in Clinical Dementia Rating - Sum of Boxes (CDR-SB) scores. CDR-SB is a semi-structured interview of participants and their caregivers. Participant's cognitive status is rated across 6 domains of functioning, including memory, orientation, judgment/problem solving, community affairs, home/hobbies, and personal care. Severity score assigned for each of 6 domains; Total score (SB) ranges from 0 to 18. Higher scores indicate greater disease severity. |
Baseline to Week 78
|
|
Functional Assessment (DAD)
Tidsramme: Baseline to Week 78
|
Change from baseline in Disability Assessment for Dementia (DAD)scores. The DAD consists of 40 items with a score range of 0-100 to evaluate the basic and instrumental activities of daily living of subjects with dementia. It is administered through an interview with the caregiver. Higher DAD scores indicate less disability or better function. |
Baseline to Week 78
|
|
Global Cognition Assessment (MMSE)
Tidsramme: Baseline to Week 78
|
Change from baseline in Mini-Mental State Examination (MMSE) score. The MMSE is a measure of global cognition that is widely used for clinical staging of Alzheimer's Disease. It consists of 11 domains items for a score range of 0-30 to assess general cognitive function. Higher score on MMSE means better cognitive skills. |
Baseline to Week 78
|
Andre resultatmål
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Imaging Biomarker Endpoint (Hippocampal Volume)
Tidsramme: Baseline to Week 78
|
Change from baseline in total (bilateral) hippocampal volume (HV) (uL) as measured by Magnetic Resonance Imaging (MRI). HV atrophy is an early event in AD patients, especially in APOE4/4 homozygotes who show accelerated atrophy compared to APOE3/3 patients with Early AD. HV may be a marker of synaptic loss and neurodegeneration. |
Baseline to Week 78
|
|
Imaging Biomarker Endpoint (Cortical Thickness [Whole Cortex])
Tidsramme: Baseline to Week 78
|
Change from baseline in total (bilateral) cortical thickness (mm) as measured by MRI. Brain MRI studies in Alzheimer's Disease patients show progressive cortical atrophy, reflecting progressive neurodegeneration. |
Baseline to Week 78
|
|
Imaging Biomarker Endpoint (Cortical Thickness [Mayo Index])
Tidsramme: Baseline to Week 78
|
Change from baseline in total (bilateral) cortical thickness (mm) as measured by MRI. Brain MRI studies in Alzheimer's Disease patients show progressive cortical atrophy, reflecting progressive neurodegeneration. The Mayo Index refers specifically to the measurement of cortical thickness in the medial temporal lobe. |
Baseline to Week 78
|
|
Imaging Biomarker Endpoint (Whole Brain Volume)
Tidsramme: Baseline to Week 78
|
Change from baseline in whole brain volume (uL) as measured by Magnetic Resonance Imaging (MRI). |
Baseline to Week 78
|
|
Imaging Biomarker Endpoint (Ventricular Volume)
Tidsramme: Baseline to Week 78
|
Change from baseline in total (bilateral) ventricular volume (uL) as measured by Magnetic Resonance Imaging (MRI). |
Baseline to Week 78
|
|
Imaging Biomarker Endpoint - DTI in Grey Matter Mean Diffusivity - Bilateral Caudate
Tidsramme: Baseline to Week 78
|
Change from baseline in Grey Matter Mean Diffusivity (Bilateral Caudate) as measured by Diffusion Tensor Imaging - Magnetic Resonance Imaging (DTI-MRI). The mean diffusivity (MD) is the average of the three main diffusion values (eigenvalues) obtained from the diffusion tensor imaging (DTI). It is expressed as mm2/s. This unit quantifies the average rate of water diffusion across all directions within a tissue, providing an overall measure of tissue microstructural properties. Lower MD value suggests better maintenance of microstructural integrity of a given brain tissue. Positive treatment effects of ALZ-801 on DTI would present as lower mean diffusivity compared with the placebo group. |
Baseline to Week 78
|
|
Imaging Biomarker Endpoint - DTI in White Matter Mean Diffusivity (Bilateral Fornix)
Tidsramme: Baseline to Week 78
|
Change from baseline in Bilateral Fornix White Matter Mean Diffusivity as measured by Diffusion Tensor Imaging - Magnetic Resonance Imaging (DTI-MRI). The mean diffusivity (MD) is the average of the three main diffusion values (eigenvalues) obtained from the diffusion tensor imaging (DTI). It is expressed as mm2/s. This unit quantifies the average rate of water diffusion across all directions within a tissue, providing an overall measure of tissue microstructural properties. Lower MD value suggests better maintenance of microstructural integrity of a given brain tissue. Positive treatment effects of ALZ-801 on DTI would present as lower mean diffusivity compared with the placebo group. |
Baseline to Week 78
|
|
Imaging Biomarker Endpoint - White Matter Fractional Anisotropy (Bilateral Fornix)
Tidsramme: Baseline to Week 78
|
Change from baseline in Bilateral Fornix White Matter Fractional Anisotropy as measured by Diffusion Tensor Imaging - Magnetic Resonance Imaging (DTI-MRI). Fractional anisotropy (FA) is a unitless, scalar value that measures the degree of anisotropic (directional) water diffusion within a voxel, ranging from 0 to 1. A value of 0 indicates perfectly isotropic (equal in all directions) diffusion, while a value of 1 indicates perfectly anisotropic (directional) diffusion. Higher FA value suggests better maintenance of microstructural integrity of a given brain tissue. Positive treatment effects of ALZ-801 on DTI would present as higher FA in the ALZ-801 group compared with the placebo group. |
Baseline to Week 78
|
|
Cognitive Efficacy Endpoint (ADAS-Cog 13) - MCI Subgroup
Tidsramme: Baseline to Week 78
|
Change from baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale 13 (ADAS-cog 13) scores at 78 weeks. The ADAS-Cog13 is a rater administered instrument that was designed to assess the severity of the dysfunction in the cognitive and noncognitive behaviors characteristic of persons with AD. The cognitive subscale of the ADAS-Cog13 consists of 13 items assessing areas of cognitive function most typically impaired in AD: orientation, verbal memory, language, praxis, delayed free recall, digit cancellation. The ADAS-Cog13 scale ranges from 0 to 85. Higher scores indicate greater disease severity. |
Baseline to Week 78
|
|
Cognitive Efficacy Endpoint (ADAS-Cog 13) - Mild Alzheimer's Disease(Mild AD) Subgroup
Tidsramme: Baseline to Week 78
|
Change from baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale 13 (ADAS-cog 13) scores at 78 weeks. The ADAS-Cog13 is a rater administered instrument that was designed to assess the severity of the dysfunction in the cognitive and noncognitive behaviors characteristic of persons with AD. The cognitive subscale of the ADAS-Cog13 consists of 13 items assessing areas of cognitive function most typically impaired in AD: orientation, verbal memory, language, praxis, delayed free recall, digit cancellation. The ADAS-Cog13 scale ranges from 0 to 85. Higher scores indicate greater disease severity. |
Baseline to Week 78
|
|
A-IADL-W - MCI Subgroup
Tidsramme: Baseline to Week 78
|
Change from baseline in Amsterdam - Instrumental Activities of Daily Living scores calculated using the weighted average method (A-IADL-W score). The A-IADL Questionnaire is a 70-item informant-based computerized questionnaire aimed at detecting deficits in complex functions at the early stages of AD. Instrumental ADL can be described as the activities necessary to function independently in society. These activities include, but are not limited to, cooking, doing finances, and shopping. They are complex everyday tasks, determined by multiple cognitive processes and controlled processing. They can be distinguished from basic ADL, which include basic self-care skills. The A-IADL-W has a score range of 0-100 and is calculated as follows: (sum of all scores / number of questions scored) × 25. For A-IADL-W, higher scores indicates worse functioning or more impairment. |
Baseline to Week 78
|
|
A-IADL-W - Mild AD Subgroup
Tidsramme: Baseline to Week 78
|
Change from baseline in Amsterdam - Instrumental Activities of Daily Living scores calculated using the weighted average method (A-IADL-W score). The A-IADL Questionnaire is a 70-item informant-based computerized questionnaire aimed at detecting deficits in complex functions at the early stages of AD. Instrumental ADL can be described as the activities necessary to function independently in society. These activities include, but are not limited to, cooking, doing finances, and shopping. They are complex everyday tasks, determined by multiple cognitive processes and controlled processing. They can be distinguished from basic ADL, which include basic self-care skills. The A-IADL-W has a score range of 0-100 and is calculated as follows: (sum of all scores / number of questions scored) × 25. For A-IADL-W, higher scores indicates worse functioning or more impairment. |
Baseline to Week 78
|
|
CDR-SB - MCI Subgroup
Tidsramme: Baseline to Week 78
|
Change from baseline in Clinical Dementia Rating - Sum of Boxes (CDR-SB) scores. CDR-SB is a semi-structured interview of participants and their caregivers. Participant's cognitive status is rated across 6 domains of functioning, including memory, orientation, judgment/problem solving, community affairs, home/hobbies, and personal care. Severity score assigned for each of 6 domains; Total score (SB) ranges from 0 to 18. Higher scores indicate greater disease severity. |
Baseline to Week 78
|
|
CDR-SB - Mild AD Subgroup
Tidsramme: Baseline to Week 78
|
Change from baseline in Clinical Dementia Rating - Sum of Boxes (CDR-SB) scores. CDR-SB is a semi-structured interview of participants and their caregivers. Participant's cognitive status is rated across 6 domains of functioning, including memory, orientation, judgment/problem solving, community affairs, home/hobbies, and personal care. Severity score assigned for each of 6 domains; Total score (SB) ranges from 0 to 18. Higher scores indicate greater disease severity. |
Baseline to Week 78
|
|
Functional Assessment (DAD) - MCI Subgroup
Tidsramme: Baseline to Week 78
|
Change from baseline in Disability Assessment for Dementia (DAD)scores. The DAD consists of 40 items with a score range of 0-100 to evaluate the basic and instrumental activities of daily living of subjects with dementia. It is administered through an interview with the caregiver. Higher DAD scores indicate less disability or better function. |
Baseline to Week 78
|
|
Functional Assessment (DAD) - Mild AD Subgroup
Tidsramme: Baseline to Week 78
|
Change from baseline in Disability Assessment for Dementia (DAD)scores. The DAD consists of 40 items with a score range of 0-100 to evaluate the basic and instrumental activities of daily living of subjects with dementia. It is administered through an interview with the caregiver. Higher DAD scores indicate less disability or better function. |
Baseline to Week 78
|
|
Global Cognition Assessment (MMSE) - MCI Subgroup
Tidsramme: Baseline to Week 78
|
Change from baseline in Mini-Mental State Examination (MMSE) score. The MMSE is a measure of global cognition that is widely used for clinical staging of Alzheimer's Disease. It consists of 11 domains items for a score range of 0-30 to assess general cognitive function. Higher score on MMSE means better cognitive skills. |
Baseline to Week 78
|
|
Global Cognition Assessment (MMSE) - Mild AD Subgroup
Tidsramme: Baseline to Week 78
|
Change from baseline in Mini-Mental State Examination (MMSE) score. The MMSE is a measure of global cognition that is widely used for clinical staging of Alzheimer's Disease. It consists of 11 domains items for a score range of 0-30 to assess general cognitive function. Higher score on MMSE means better cognitive skills. |
Baseline to Week 78
|
|
Hippocampal Volume (MCI Subgroup)
Tidsramme: Baseline to Week 78
|
Change from baseline in total (bilateral) hippocampal volume (HV) (uL) as measured by Magnetic Resonance Imaging (MRI). HV atrophy is an early event in AD patients, especially in APOE4/4 homozygotes who show accelerated atrophy compared to APOE3/3 patients with Early AD. HV may be a marker of synaptic loss and neurodegeneration. |
Baseline to Week 78
|
|
Hippocampal Volume (Mild AD Subgroup)
Tidsramme: Baseline to Week 78
|
Change from baseline in total (bilateral) hippocampal volume (HV) (uL) as measured by Magnetic Resonance Imaging (MRI). HV atrophy is an early event in AD patients, especially in APOE4/4 homozygotes who show accelerated atrophy compared to APOE3/3 patients with Early AD. HV may be a marker of synaptic loss and neurodegeneration. |
Baseline to Week 78
|
|
Cortical Thickness (Whole Cortex) (MCI Subgroup)
Tidsramme: Baseline to Week 78
|
Change from baseline in total (bilateral) cortical thickness (mm) as measured by MRI. Brain MRI studies in Alzheimer's Disease patients show progressive cortical atrophy, reflecting progressive neurodegeneration. |
Baseline to Week 78
|
|
Cortical Thickness (Whole Cortex) (Mild AD Subgroup)
Tidsramme: Baseline to Week 78
|
Change from baseline in total (bilateral) cortical thickness (mm) as measured by MRI. Brain MRI studies in Alzheimer's Disease patients show progressive cortical atrophy, reflecting progressive neurodegeneration. |
Baseline to Week 78
|
|
Cortical Thickness (Mayo Index) (MCI Subgroup)
Tidsramme: Baseline to Week 78
|
Change from baseline in total (bilateral) cortical thickness (mm) as measured by MRI. Brain MRI studies in Alzheimer's Disease patients show progressive cortical atrophy, reflecting progressive neurodegeneration. The Mayo Index refers specifically to the measurement of cortical thickness in the medial temporal lobe versus the whole cortex. |
Baseline to Week 78
|
|
Cortical Thickness (Mayo Index) (Mild AD Subgroup)
Tidsramme: Baseline to Week 78
|
Change from baseline in total (bilateral) cortical thickness (mm) as measured by MRI. Brain MRI studies in Alzheimer's Disease patients show progressive cortical atrophy, reflecting progressive neurodegeneration. The Mayo Index refers specifically to the measurement of cortical thickness in the medial temporal lobe versus the whole cortex. |
Baseline to Week 78
|
|
Whole Brain Volume (MCI Subgroup)
Tidsramme: Baseline to Week 78
|
Change from baseline in whole brain volume (uL) as measured by Magnetic Resonance Imaging (MRI). |
Baseline to Week 78
|
|
Whole Brain Volume (Mild AD Subgroup)
Tidsramme: Baseline to Week 78
|
Change from baseline in whole brain volume (uL) as measured by Magnetic Resonance Imaging (MRI). |
Baseline to Week 78
|
|
Ventricular Volume (MCI Subgroup)
Tidsramme: Baseline to Week 78
|
Change from baseline in total (bilateral) ventricular volume (uL) as measured by Magnetic Resonance Imaging (MRI). |
Baseline to Week 78
|
|
Ventricular Volume (Mild AD Subgroup)
Tidsramme: Baseline to Week 78
|
Change from baseline in total (bilateral) ventricular volume (uL) as measured by Magnetic Resonance Imaging (MRI). |
Baseline to Week 78
|
|
Cognitive Efficacy Endpoint (ADAS-Cog 13) - Female Subgroup of the FAS
Tidsramme: Baseline to Week 78
|
Change from baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale 13 (ADAS-cog 13) scores at 78 weeks. The ADAS-Cog13 is a rater administered instrument that was designed to assess the severity of the dysfunction in the cognitive and noncognitive behaviors characteristic of persons with AD. The cognitive subscale of the ADAS-Cog13 consists of 13 items assessing areas of cognitive function most typically impaired in AD: orientation, verbal memory, language, praxis, delayed free recall, digit cancellation. The ADAS-Cog13 scale ranges from 0 to 85. Higher scores indicate greater disease severity. |
Baseline to Week 78
|
|
Cognitive Efficacy Endpoint (ADAS-Cog 13) - Male Subgroup of the FAS
Tidsramme: Baseline to Week 78
|
Change from baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale 13 (ADAS-cog 13) scores at 78 weeks. The ADAS-Cog13 is a rater administered instrument that was designed to assess the severity of the dysfunction in the cognitive and noncognitive behaviors characteristic of persons with AD. The cognitive subscale of the ADAS-Cog13 consists of 13 items assessing areas of cognitive function most typically impaired in AD: orientation, verbal memory, language, praxis, delayed free recall, digit cancellation. The ADAS-Cog13 scale ranges from 0 to 85. Higher scores indicate greater disease severity. |
Baseline to Week 78
|
|
A-IADL-W - Female Subgroup
Tidsramme: Baseline to Week 78
|
Change from baseline in Amsterdam - Instrumental Activities of Daily Living scores calculated using the weighted average method (A-IADL-W score). The A-IADL Questionnaire is a 70-item informant-based computerized questionnaire aimed at detecting deficits in complex functions at the early stages of AD. Instrumental ADL can be described as the activities necessary to function independently in society. These activities include, but are not limited to, cooking, doing finances, and shopping. They are complex everyday tasks, determined by multiple cognitive processes and controlled processing. They can be distinguished from basic ADL, which include basic self-care skills. The A-IADL-W has a score range of 0-100 and is calculated as follows: (sum of all scores / number of questions scored) × 25. For A-IADL-W, higher scores indicates worse functioning or more impairment. |
Baseline to Week 78
|
|
A-IADL-W - Male Subgroup
Tidsramme: Baseline to Week 78
|
Change from baseline in Amsterdam - Instrumental Activities of Daily Living scores calculated using the weighted average method (A-IADL-W score). The A-IADL Questionnaire is a 70-item informant-based computerized questionnaire aimed at detecting deficits in complex functions at the early stages of AD. Instrumental ADL can be described as the activities necessary to function independently in society. These activities include, but are not limited to, cooking, doing finances, and shopping. They are complex everyday tasks, determined by multiple cognitive processes and controlled processing. They can be distinguished from basic ADL, which include basic self-care skills. The A-IADL-W has a score range of 0-100 and is calculated as follows: (sum of all scores / number of questions scored) × 25. For A-IADL-W, higher scores indicates worse functioning or more impairment. |
Baseline to Week 78
|
|
CDR-SB - Female Subgroup
Tidsramme: Baseline to Week 78
|
Change from baseline in Clinical Dementia Rating - Sum of Boxes (CDR-SB) scores. CDR-SB is a semi-structured interview of participants and their caregivers. Participant's cognitive status is rated across 6 domains of functioning, including memory, orientation, judgment/problem solving, community affairs, home/hobbies, and personal care. Severity score assigned for each of 6 domains; Total score (SB) ranges from 0 to 18. Higher scores indicate greater disease severity. |
Baseline to Week 78
|
|
CDR-SB - Male Subgroup
Tidsramme: Baseline to Week 78
|
Change from baseline in Clinical Dementia Rating - Sum of Boxes (CDR-SB) scores. CDR-SB is a semi-structured interview of participants and their caregivers. Participant's cognitive status is rated across 6 domains of functioning, including memory, orientation, judgment/problem solving, community affairs, home/hobbies, and personal care. Severity score assigned for each of 6 domains; Total score (SB) ranges from 0 to 18. Higher scores indicate greater disease severity. |
Baseline to Week 78
|
|
Functional Assessment (DAD) - Female Subgroup
Tidsramme: Baseline to Week 78
|
Change from baseline in Disability Assessment for Dementia (DAD)scores. The DAD consists of 40 items with a score range of 0-100 to evaluate the basic and instrumental activities of daily living of subjects with dementia. It is administered through an interview with the caregiver. Higher DAD scores indicate less disability or better function. |
Baseline to Week 78
|
|
Functional Assessment (DAD) - Male Subgroup
Tidsramme: Baseline to Week 78
|
Change from baseline in Disability Assessment for Dementia (DAD)scores. The DAD consists of 40 items with a score range of 0-100 to evaluate the basic and instrumental activities of daily living of subjects with dementia. It is administered through an interview with the caregiver. Higher DAD scores indicate less disability or better function. |
Baseline to Week 78
|
|
Treatment Emergent Adverse Events (TEAE) - Females
Tidsramme: Entire study: approximately 82 weeks. (first dose of study drug until end of Safety Follow-up Visit at 28 +/- 7 days after the last dose (ie, 78-week treatment period plus 4-weeks follow-up after last dose up to total of 82 weeks)
|
Safety and tolerability as measured by incidence of treatment emergent adverse events (TEAE), serious TEAEs, and TEAEs experienced by at least 5% of participants in either treatment group |
Entire study: approximately 82 weeks. (first dose of study drug until end of Safety Follow-up Visit at 28 +/- 7 days after the last dose (ie, 78-week treatment period plus 4-weeks follow-up after last dose up to total of 82 weeks)
|
|
Treatment Emergent Adverse Events (TEAE) - Males
Tidsramme: Entire study: approximately 82 weeks. (first dose of study drug until end of Safety Follow-up Visit at 28 +/- 7 days after the last dose (ie, 78-week treatment period plus 4-weeks follow-up after last dose up to total of 82 weeks)
|
Safety and tolerability as measured by incidence of treatment emergent adverse events (TEAE), serious TEAEs, and TEAEs experienced by at least 5% of participants in either treatment group |
Entire study: approximately 82 weeks. (first dose of study drug until end of Safety Follow-up Visit at 28 +/- 7 days after the last dose (ie, 78-week treatment period plus 4-weeks follow-up after last dose up to total of 82 weeks)
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Samarbejdspartnere
Samarbejdspartnere
Efterforskere
Efterforskere
- Ledende efterforsker: Susan Abushakra, MD, Alzheon Inc.
Publikationer og nyttige links
Generelle publikationer
- Hey JA, Abushakra S, Power A, Watson D, Porsteinsson A, Sabbagh M, MacSweeney E, Cohen S, Boada M, Doraiswamy PM, Elahi FM, Rissman RA, Liang E, Flint S, Hristova E, Kesslak P, McLaine R, Albayrak A, Schaefer JF, Yu JY, Tolar L, Tolar M. Plasma Biomarker Effects of Oral Valiltramiprosate/ALZ-801 in Early Alzheimer's Disease from Phase 3 and Phase 2 Trials: Analysis of Core Biomarkers and Correlations with Clinical and Neuroimaging Outcomes. Drugs. 2026 Sep 1. doi: 10.1007/s40265-026-02381-3. Online ahead of print.
- Abushakra S, Power A, Watson D, Porsteinsson A, Sabbagh M, MacSweeney E, Cohen S, Boada Rovira M, Doraiswamy PM, Liang E, Flint S, Kesslak JP, McLaine R, Albayrak A, Schaefer J, Yu J, Tolar L, Dickson S, Hey JA, Tolar M. Clinical Efficacy, Safety and Imaging Effects of Oral Valiltramiprosate in APOEepsilon4/epsilon4 Homozygotes with Early Alzheimer's Disease: Results of the Phase III, Randomized, Double-Blind, Placebo-Controlled, 78-Week APOLLOE4 Trial. Drugs. 2025 Nov;85(11):1455-1472. doi: 10.1007/s40265-025-02250-5. Epub 2025 Sep 28.
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Faktiske)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- ALZ-801-AD301
- R01AG065253 (U.S. NIH-bevilling/kontrakt)
- 2020-005755-20 (EudraCT nummer)
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .